Summary
Thirty-five diabetic patients (mean age 60) underwent regularly controlled treatment for an average of 7 months with 2 1/2 to 20 mg of glipizide daily, the mean dose being almost 10 mg/daily. These patients had been diabetics for an average of 9 years, most had been previously treated with other sulphonamides, one third were obese and 90% had degenerative complications and/or an associated disease. Results showed a 23% mean decrease in mean blood sugar levels and a 21% decrease in maximal blood sugar levels during the day. There was an increase in the number of well or very well controlled patients and a decrease of non-satisfactory results. Renal, hepatic and haematologic monitoring reveared no abnormalities. Minor hypoglycaemic manifestations were not uncommon. Two severe hypoglycaemic attacks occurred in older patients with renal insufficiency associated with hepatic dysfunction. Glipizide is contra-indicated when kidney function is reduced by more than 3/4 and additional caution seems to be necessary in the event of associated hepatic damage. The drug appears to enhance the antiprothrombin action of anticoagulants.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ambrogi, V., Bloch, K., Daturi, S., Griggi, P., Logemann, W., Parenti, M.A., Rabini, T., Tommasini, R.: New oral antidiabetic drugs. Arzneimittelforsch.21, 200–208 (1971).
Ambrogi, V., Bloch, K., Daturi, S., Griggi, P., Logemann, W., Mandelli, V., Parenti, A., Rabini, T., Usardi, M.M., Tommasini, R.: Pharmacological study of a new oral antidiabetic: N-(4-(β-(5-methylpyrazi-ne 2-carboxamido)-ethyl)-benzenesulfonyl)-N′-cyclohexylurea or K 4024. Arzneimittelforsch.21, 208–215 (1971)
Berger, W.: 88 schwere Hypoglykämiezwischenfälle unter der Behandlung mit Sulfonyl-Harnstoffen. Resultate einer gesamtschweizerischen Umfrage in den Jahren 1968 und 1969. Schweiz. med. Wschr.101, 1013–1022 (1971)
Berger, W., Spring, P.: Veränderung der Pharmakokinetik oraler Antidiabetika durch medikamentöse Interferenz und Niereninsuffizienz. Dtsch. med. Wschr.95, 2525–2527 (1970)
Fabre, J.: Comment prescrire les médicaments en présence de fonctions rénales déficientes ? Tables d'adaptation posologique. Schweiz. med. Wschr.102, 251–256 (1972)
Fabre, J., Balant, L., Zahnd, G.: Influence de fonctions rénales déficientes sur le comportement de la glipizide (sulfonylurée hypoglycémiante) et de ses métabolites. Montpellier: C.-R. Soc. Néphrologie, 1972
Fuccella, L.M., Tamassia, V., Valzelli, G.: Metabolism and kinetics of the hypoglycaemic agent glipizide in man —Comparison with glibenclamide. J. clin. Pharmacol. (In press)
Greco, A.V., Fedeli, G., Chiranda, G., Lucente, M., Accietto, F., Fenici, R.: Esperienze cliniche sull'azione du un nuovo antidiabetico orale: la glydiazinamide. Minerva med.62, 2829–2839, (1971)
Haupt, E., Köberich, W., Bemer, J.: Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. Diabetologia7, 449–460 (1971)
Hazard, J., Domart, A.: Deux cas d'hémiplégie révélatrice d'une hypoglycémie sévère provoquée par les sulfamides hypoglycémiants Bull. Soc. Méd. Paris.116, 473–476 (1965)
Lamotte, M., Segrestaa, J.M., Martin, E., Vilde, J.L.: Hypoglycémie mortelle par sulfamide hypoglycémiant chez un patient porteur d'un adénome du cortex surrénal et d'une insuffisance rénale. Sem. Hôp. Paris41, 2371–2374 (1965)
Laroche, Cl., Nenna, A., Cremer, G., Caquet, R.: Hypoglycémies graves chez les diabétiques traités par les sulfamides hypoglycémiants. Bull. Soc. Méd. Paris116, 461–466 (1965)
Loubatieres, A., Mariani, M.M., Ribes, G.: Pharmacological study of a new hypoglycaemic sulfonamide, glisoxepid (R.P. 22.410). Diabetologia8, 29–36 (1972)
Marigo, S., Del Novo, G., Bini, P.P., Sacchetti, G.: Pharmacological methods for evaluating a new hypoglycaemic agent in humans: a multiple design. Arzneimittel-Forsch.21, 215–220 (1971)
Masbernard, A., Portal, A.: Le vrai problème du diabète. Essai du gliclazide, molécule originale à propriétés métaboliques et vasculaires. Thérapeutique48, 569–574 (1972)
Montgolfier, R. de, Kressmann, J., Plauchu, M.: Les accidents hypoglycémiques des sulfamides antidiabétiques. Lyon med.225, 97–108 (1971)
Nissen-Druey, C., Berger, W., Huber, F.: Hypoglykämien bei der Anwendung oraler Antidiabetika. Praxis59, 53–57 (1970)
Parodi, F.A.: Pharmacological and clinical evaluation of the activity of a new oral antidiabetic, glydiazinamide (K 2024). (Unpublished report).
Pedrazzi, F., Pisani Ceretti, A., Losi, S., Bommartini, F., Artini, D., Emanueli, A.: Evaluation in hospitalized subjects of a new hypoglycaemic sulfonylurea, glydiazinamide Arzneimittel-Forsch.21, 220–225 (1971)
Reidenberg, M.M.: Renal function and drug action. London: W.B. Saunders Co. 1971
Schach von Wittenau, M.: Metabolism of K 2024 (glydiazinamide) in man, dog, rat and mouse. (Unpublished report)
Vazquez Rodriguez, J.J., Barreira Tella, P., Ortiz Vazquez, J.: Hipoglicemias por antidiabeticos orales. Rev. clin. esp.118, 21–30 (1970)
Vazquez, A., Moya, G.G., Ricoy, J.R.: Aspectos neurologicos de los comas hipoglicemicos de origen medico por uso de hipoglicemiantes. Rev. clin. esp.117, 158–168 (1970)
Viars, P., Seebacher, J.: Les interférences médicamenteuses. Risques thérapeutiques et incompatibilités. Paris: Arnette Edit. 1971
Author information
Authors and Affiliations
Additional information
We would like to express our thanks to Pfizer Laboratories for having made available the drug necessary for this study.
Rights and permissions
About this article
Cite this article
Masbernard, A., Giudicelli, C. & Massey, J. Clinical experience with glipizide in the treatment of mostly complicated diabetes. Diabetologia 9 (Suppl 1), 356–363 (1973). https://doi.org/10.1007/BF01218447
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01218447